High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases

Area of Science:

• Bioinformatics and Computational Biology
• Molecular Pharmacology
• Genomics and Systems Biology

Background:

• Molecular reductionism oversimplifies complex human physiology, aging, and drug efficacy.
• High-dimensionality (H-D) data from omics (transcriptomics, proteomics, metabolomics, epigenomics) offers deeper insights into disease complexity.
• Accessible H-D datasets for complex diseases like metabolic syndrome, cardiovascular disease, and Alzheimer's disease are increasingly available.

Purpose of the Study:

• To highlight the necessity of advanced bioinformatic platforms for interpreting H-D data in age-related diseases.
• To emphasize the synergy between understanding disease pathology and therapeutic drug response using computational approaches.
• To advocate for novel informatics processes for drug discovery and repurposing in aging-related diseases.

Main Methods:

• Utilizing high-dimensionality data streams (transcriptomic, proteomic, metabolomic, epigenomic).
• Employing advanced bioinformatic platforms for data interrogation and analysis.
• Exploring novel informatics processes like latent semantic indexing and topological data analysis.

Main Results:

• H-D data analysis enhances the appreciation of biologic disease and drug response complexity.
• Computational approaches facilitate the synergy between understanding disease pathology and therapeutic signaling.
• Elucidation of H-D molecular disease signatures can refine therapeutic strategies for age-related diseases.

Conclusions:

• Effective interpretation of H-D data is imperative for developing multidimensional therapeutics with engineered efficacy.
• Informatic platforms should integrate with advanced chemical, drug, and phenotypic analytical models for drug prioritization and repurposing.
• A realistic appreciation of complex human diseases and drug effects is essential for future therapeutic development.